Form 4: HealthEquity Founder Stephen Neeleman Reports Stock Transactions
SEC Form 4 Filing
Stephen Neeleman, Founder and Vice Chairman of HealthEquity, reports acquisition and disposal of common stock and derivative securities.
Summary
- Stephen Neeleman, Founder and Vice Chairman of HealthEquity, filed a Form 4 detailing changes in beneficial ownership.
- On March 27, 2024, Neeleman acquired 10,976 shares of common stock and 15,970 shares of common stock.
- Following these transactions, Neeleman directly owns 99,598 shares of common stock.
- Neeleman also indirectly owns 559,235 shares through the Stephen and Christine Neeleman Trust and 203,000 shares through Neeleman Family Holdings, LLC.
- The report also details ownership of stock options with various exercise prices and expiration dates.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing of stock transactions. The acquisition of shares could be seen as a slightly positive sign, but it's not definitive.
Positives
- The acquisition of shares by a company founder and executive could be interpreted as a positive signal about their confidence in the company's future.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings to gauge sentiment and potential future actions.
Comparison to Industry Standards
- Insider trading activity is common across publicly traded companies, and Form 4 filings are a standard practice.
- The size and frequency of insider transactions can vary widely depending on the company's size, industry, and specific circumstances.
- Comparing Neeleman's transactions to those of other executives in similar healthcare or financial technology companies could provide additional context.
Stakeholder Impact
- The transactions could have a minor impact on shareholder sentiment, depending on how they interpret the insider activity.
- Employees may view the insider activity as a reflection of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of stock and restricted stock unit transactions. |
| 03/28/2024 | Date of signature on the Form 4. |
| 04/01/2025 | First vesting date for 25% of the restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.